News Case study backs YolTech's AATD gene therapy A gene therapy for alpha-1 antitrypsin deficiency developed by China's YolTech has successfully treated a patient with a severe form of the disease.
News uniQure set for May FDA verdict on Huntington's gene therapy The FDA has started its review of uniQure's gene therapy for neurodegenerative disorder Huntington's, but will require an advisory committee meeting.
News Ultragenyx wins FDA approval for first treatment targeting r... Ultragenyx secured its first gene therapy approval, the FDA clearing GENGLYCOS as the first treatment designed to address underlying cause of GSDla.
News Skylark trials gene therapy for common form of child deafnes... Skylark Bio has dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.
R&D Purespring on nephrology & gene therapy in kidney disease Purespring CEO Haseeb Ahmad discusses transforming the treatment of kidney disease, an area of enormous unmet need, and the company's gene therapy.
News Regenxbio's Duchenne gene therapy clears phase 3 hurdle Regenxbio is pitching at FDA approval in 2027 for its Duchenne muscular dystrophy gene therapy RGX-202, a potential rival to Sarepta/Roche's Elevidys.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.